CN110577518B - Methyl indole and amide side chain amino acid modified diketopiperazine, synthesis and application thereof - Google Patents
Methyl indole and amide side chain amino acid modified diketopiperazine, synthesis and application thereof Download PDFInfo
- Publication number
- CN110577518B CN110577518B CN201810596333.3A CN201810596333A CN110577518B CN 110577518 B CN110577518 B CN 110577518B CN 201810596333 A CN201810596333 A CN 201810596333A CN 110577518 B CN110577518 B CN 110577518B
- Authority
- CN
- China
- Prior art keywords
- lys
- diketopiperazine
- methyl
- indole
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 amide side chain amino acid modified diketopiperazine Chemical class 0.000 title description 4
- BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical compound C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 title description 2
- 230000015572 biosynthetic process Effects 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 206010027476 Metastases Diseases 0.000 claims abstract description 18
- 230000009401 metastasis Effects 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 13
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 206010028980 Neoplasm Diseases 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 28
- 150000001875 compounds Chemical class 0.000 description 16
- 239000006285 cell suspension Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 239000002504 physiological saline solution Substances 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 5
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 5
- 210000001099 axilla Anatomy 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003169 placental effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000002001 anti-metastasis Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了下式的3R‑(吲哚‑3‑甲基)‑6R‑[4‑Lys(AA)‑氨基正丁基]‑2,5‑二酮哌嗪(式中AA为L‑Lys残基和L‑Thr残基),公开了它们的制备方法,公开了它们的抗肿瘤活性,公开了它们的抗肿瘤转移活性,因而本发明公开了它们在制备抗肿瘤药物和抗肿瘤转移药物中的应用。
The invention discloses 3R-(indole-3-methyl)-6R-[4-Lys(AA)-amino-n-butyl]-2,5-diketopiperazine of the following formula (where AA is L- Lys residue and L-Thr residue), their preparation method is disclosed, their anti-tumor activity is disclosed, and their anti-tumor metastasis activity is disclosed, so the present invention discloses their use in the preparation of anti-tumor drugs and anti-tumor metastasis application in medicine.
Description
Technical Field
The invention relates to 3R- (indole-3-methyl) -6R- [4-Lys (AA) -amino n-butyl ] -2, 5-diketopiperazine, a preparation method thereof, antitumor activity thereof and antitumor metastasis activity thereof, and thus the invention relates to application thereof in preparing antitumor drugs and antitumor metastasis drugs. The invention belongs to the field of biological medicine.
Background
Tumors seriously threaten the health of human beings. In addition to the poor prognosis of patients with tumors by themselves, metastasis associated with tumors further worsens the prognosis of patients. For example, more than 90% of patients with tumors die from metastases. Because the existing antitumor drugs have no effect of resisting tumor metastasis, the clinical curative effect of tumor chemotherapy is not ideal. The invention relates to a medicament for resisting tumor metastasis, which is an urgent clinical need. The inventors have previously disclosed that diketopiperazines of the four S, S-, R, R-, R, S-and S, R-configurations inhibit migration and invasion of HCCLM3 (highly metastatic human liver cancer cells) at a concentration of 0.5. mu.M. Later, the inventors further disclosed that R, R-configured diketopiperazines inhibit tumor metastasis to the lung in C57BL/6 mice at a minimum effective dose of 5. mu. mol/kg/day. To reduce the minimum effective dose, the inventors have developed various modifications to the butylamino group of the diketopiperazine in the R, R-configuration. After 3 years of exploration, the acylation of the 4-amino-n-butyl group of diketopiperazines of R, R-configuration with L-Lys and L-Lys acylated side chain amino groups was found to reduce the minimum effective dose against tumor metastasis to 0.5. mu. mol/kg/day. The 10-fold reduction of the lowest effective dose indicates that the structural modification has outstanding technical effects. They were also effective in inhibiting tumor growth in S180 mice at a dose of 0.5. mu. mol/kg/day. This additional anti-tumor effect indicates a prominent technical effect of this structural modification. Based on these findings, the inventors have proposed the present invention.
Disclosure of Invention
The first aspect of the present invention is to provide 3R- (indol-3-methyl) -6R- [4-Lys (AA) -amino-n-butyl ] -2, 5-diketopiperazine of the formula (wherein AA is a L-Lys residue and a L-Thr residue).
The second aspect of the present invention provides a process for synthesizing 3R- (indole-3-methyl) -6R- [4-Lys (AA) -amino-n-butyl ] -2, 5-diketopiperazine (AA is L-Lys residue and L-Thr residue), which comprises:
(1) D-Boc-Lys (Cbz) is coupled with D-Trp-OBzl to obtain D-Boc-Lys (Cbz) -D-Trp-OBzl;
(2) D-Boc-Lys (Cbz) -D-Trp-OBzl removes Boc protecting group in 4N hydrogen chloride/ethyl acetate solution to obtain D-Lys (Cbz) -D-Trp-OBzl;
(3) cyclizing D-Lys (Cbz) -D-Trp-OBzl in ethyl acetate containing 5% sodium bicarbonate water solution to obtain 3R- (indole-3-methyl) -6R- (4-benzyloxycarbonylamino n-butyl) -2, 5-diketopiperazine (1);
(4)1 catalyzing hydrogen to remove carbobenzoxy to obtain 3R- (indole-3-methyl) -6R- [ 4-amino-n-butyl ] -2, 5-diketopiperazine (2);
(5)2 is coupled with L-Boc-Lys (Cbz) to obtain 3R- (indole-3-methyl) -6R- [4-Boc-Lys (Cbz) -amino n-butyl ] -2, 5-diketopiperazine (3);
(6)3, removing benzyloxycarbonyl by catalytic hydrogenolysis to obtain 3R- (indole-3-methyl) -6R- (4-Boc-Lys-amino n-butyl) -2, 5-diketopiperazine (4);
(7)4 and Boc-AA (AA is L-Lys residue and L-Thr residue) to obtain 3R- (indole-3-methyl) -6R- [4-Boc-Lys (Boc-AA) -amino n-butyl ] -2, 5-diketopiperazine (5a, b);
(8)5a, b in 4N hydrogen chloride/ethyl acetate solution to remove Boc protecting group to obtain 3R- (indole-3-methyl) -6R- [4-Lys (AA) -amino N-butyl ] -2, 5-diketopiperazine (6a, b).
In the third aspect of the present invention, 3R- (indole-3-methyl) -6R- [4-Lys (AA) -amino-n-butyl ] -2, 5-diketopiperazine (6a, b) was evaluated for its activity in inhibiting the metastasis of lung cancer in C57BL/6 mice.
The fourth aspect of the present invention is to evaluate the inhibition of tumor growth in S180 mice by 3R- (indole-3-methyl) -6R- [4-Lys (AA) -amino-n-butyl ] -2, 5-diketopiperazine (6a, b).
Drawings
FIG. 13R- (indol-3-methyl) -6R- [4-Lys (AA) -amino-n-butyl]-2, 5-diketopiperazines (6a, b) wherein AA is an L-Lys residue in 5a and 6 a; AA in 5b and 6b is an L-Thr residue; i) dicyclohexylcarbodiimide (DCC), 1-hydroxybenzotriazole (HOBt), N-methylmorpholine (NMM), Tetrahydrofuran (THF); ii)4N hydrogen chloride-ethyl acetate reagent; iii) ethyl acetate, 5% sodium bicarbonate; iv) Dimethylformamide (DMF), Pd/C, H2。
Detailed Description
To further illustrate the invention, a series of examples are given below. These examples are purely illustrative and are intended to be a detailed description of the invention only and should not be taken as limiting the invention.
EXAMPLE 1 preparation of D-Boc-Lys (Cbz) -D-Trp-OBzl
7.7g (20mmol) of D-Boc-Lys (Cbz) was suspended in 100mL of anhydrous Tetrahydrofuran (THF), and 2.7g (20mmol) of 1-hydroxybenzotriazole (HOBt) and 5.0g (25mmol) of Dicyclohexylcarbodiimide (DCC) were added to the suspension in this order under ice bath, followed by stirring for 30 min. Then, 8.0g (25mmol) of D-Trp-OBzl was added. The reaction mixture was adjusted to pH 9 by dropwise addition of N-methylmorpholine (NMM). The reaction mixture was stirred first for 1h on ice and then for 12h at room temperature. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was dissolved in 150mL of ethyl acetate solution. The ethyl acetate solution obtained was successively treated with 5% KHSO4Washing with aqueous solution for 3 times to saturate NaCl aqueous solution, 3 times. Anhydrous Na for ethyl acetate layer2SO4Drying for 12h, filtering, and concentrating the filtrate under reduced pressure to dryness. The resulting yellow syrup was purified by silica gel column Chromatography (CH)2Cl2/CH3OH,100:1) 12.0g (88%) of the title compound are obtained as a colorless powder. ESI-MS (M/e):657[ M + H]+。
EXAMPLE 2 preparation of D-Lys (Cbz) -D-Trp-OBzl
3.8g (5mmol) D-Boc-Lys (Cbz) -D-Trp-OBzl were slowly mixed with 52mL of hydrogen chloride in ethyl acetate (4M) with stirring in an ice bath. The resulting solution was stirred in an ice bath for 5 h. After that, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in 50mL of anhydrous ethyl acetate, and the resulting solution was concentrated under reduced pressure. This operation was repeated three times. The residue was washed thoroughly with anhydrous ether to give 3.41g (93%) of the title compound as a yellow powder. ESI-MS (M/e):557[ M + H ]]+。
Example 33R- (indole-3-methyl) -6R- (4-benzyloxycarbonylamino-n-butyl) -2, 5-diketopiperazine (1)
3.45g (6.2mmol) D-Lys (Cbz) -D-Trp-OBzl were dissolved in 150mL ethyl acetate. After the resulting solution was washed three times with a 5% aqueous solution of sodium hydrogencarbonate, the ethyl acetate solution was stirred at room temperature for 12 hours to sufficiently precipitate a colorless solid. 1.8g (51%) of the title compound are filtered off. ESI-MS (M/e):449[ M + H ]]+。
EXAMPLE 4 preparation of 3R- (indole-3-methyl) -6R- (4-amino-n-butyl) -2, 5-diketopiperazine (2)
To a solution of 1.9g (4.2mmol) of 3R- (indole-3-methyl) -6R- (4-benzyloxycarbonylamino N-butyl) -2, 5-diketopiperazine (1) in 20mL of anhydrous N, N-Dimethylformamide (DMF) was added 200mg of Pd/C, and H was bubbled through2The reaction was stirred at room temperature for 12 h. Pd/C was filtered off, and the filtrate was concentrated under reduced pressure to give 1.2g (92%) of the title compound as a colorless powder. ESI-MS (M/e) 315[ M + H ]]+。
EXAMPLE 5 preparation of 3R- (indole-3-methyl) -6R- [4-Boc-Lys (Cbz) -amino-n-butyl ] -2, 5-diketopiperazine (3)
Using the method of example 1, from 4.18g (11mmol) Boc-Lys (Cbz) and 3.14g (10.0mmol)3R- (indole-3-methyl) -6R- (4-amino-n-butyl) -2, 5-diketopiperazine (2) 5.17g (76 g)%) the title compound as a colorless solid. ESI-MS (M/e):677[ M + H]+；1H NMR(300MHz,DMSO-d6):δ/ppm＝10.852(s,1H),8.045(d,J＝1.8Hz,1H),7.916(d,J＝1.8Hz,1H),7.581(m,2H),7.345(m,6H),7.223(t,J＝5.4Hz1H),7.025(m,2H),6.930(t,J＝6.9Hz,1H),6.714(d,J＝8.4Hz,1H),4.115(m,1H),3.812(m,1H),3.499(m,1H),3.206(dd,J1＝16.5Hz,J2＝3.9Hz,1H),3.172(d,J＝3.9Hz,1H),2.993(m,3H),2.764(m,2H),1.478(m,2H),1.381(m,11H),1.426(m,2H),0.971(m,3H),0.600(m,3H)。
EXAMPLE 6 preparation of 3R- (indole-3-methyl) -6R- (4-Boc-Lys-amino-n-butyl) -2, 5-diketopiperazine (4)
From 3R- (indole-3-methyl) -6R- [4-Boc-Lys (Cbz) -amino-n-butyl using the procedure of example 4]1.65g (2.44mmol) of (E) -2, 5-diketopiperazine (3) give 1.49g (90%) of the title compound as a colorless powder. ESI-MS (M/e):543[ M + H]+。
EXAMPLE 7 preparation of 3R- (indole-3-methyl) -6R- [4-Boc-Lys (Boc) -amino-n-butyl ] -2, 5-diketopiperazine (5a)
From 1.14g (3.3mmol) Boc-Lys (Boc) and 1.49g (2.75mmol)3R- (indole-3-methyl) -6R- (4-Boc-Lys-amino-n-butyl) -2, 5-diketopiperazine (4) 1.57g (66%) of the title compound was obtained as colorless powder using the method of example 1. ESI-MS (M/e):771[ M + H]+；1H NMR(300MHz,DMSO-d6):δ/ppm＝10.847(s,1H),8.023(s,1H),7.915(s,1H),7.741(m,1H),7.580(m,2H),7.302(m,1H),7.048(s,1H),7.027(t,J＝8.1Hz 1H),6.930(t,J＝8.1Hz 1H),4.116(m,1H),3.814(m,2H),3.499(m,1H),3.256(dd,J1＝13.8Hz,J2＝3.0Hz,1H),3.033(m,3H),2.886(m,2H),2.738(m,2H),1.508(m,4H),1.375(m,22H),1.242(m,4H),0.975(m,3H),0.595(m,3H)。
EXAMPLE 8 preparation of 3R- (indole-3-methyl) -6R- [4-Boc-Lys (Boc-Thr) -amino-n-butyl ] -2, 5-diketopiperazine (5b)
From 1.05g (3.3mmol) Boc-Thr and 1.49g (2.75mmol)3R- (indole-3-methyl) -6R- (4-Boc-Lys-amino-n-butyl) -2, 5-diketopiperazine (4) 1.45g (71%) of the title compound were obtained as colorless powder using the method of example 1. ESI-MS (M/e):744[ M + H]+；1H NMR(300MHz,DMSO-d6):δ/ppm＝10.861(s,1H),8.052(s,1H),7.930(s,1H),7.769(m,1H),7.587(m,2H),7.297(d,J＝8.1Hz 1H),7.039(s,1H),7.020(t,J＝7.2Hz 1H),6.923(t,J＝7.2Hz 1H),6.729(d,J＝8.1Hz 1H),6.262(d,J＝8.1Hz 1H),4.722(d,J＝6.0Hz 1H),4.114(m,1H),3.873(m,1H),3.802(m,2H),3.489(m,1H),3.252(dd,J1＝14.4Hz,J2＝3.6Hz,1H),3.020(m,3H),2.758(m,2H),1.471(m,2H),1.384(m,20H),1.236(m,2H),1.018(d,J＝6.0Hz 1H),0.955(m,3H),0.565(m,3H)。
EXAMPLE 9 preparation of 3R- (indole-3-methyl) -6R- [4-Lys (Lys) -amino-n-butyl ] -2, 5-diketopiperazine (6a)
From 3R- (indole-3-methyl) -6R- [4-Boc-Lys (Boc)) amino-n-butyl using the procedure of example 2]515mg (0.67mmol) of (E) -2, 5-diketopiperazine (5a) gave 20.0mg (5.2%) of the title compound as a pale yellow powder. ESI-MS (M/e):571[ M + H]+；1H NMR(300MHz,DMSO-d6):δ/ppm＝11.000(s,1H),8.579(m,1H),8.510(m,1H),8.082(s,1H),8.038(s,1H),7.584(d,J＝7.5Hz,1H),7.322(d,J＝7.5Hz,1H),7.041(s,1H),6.930(t,J＝6.9Hz 1H),6.839(t,J＝6.9Hz 1H),4.113(m,1H),3.865(m,1H),3.733(m,1H),3.512(m,1H),3.253(m,1H),3.125(m,1H),3.051(m,2H),2.824(m,2H),2.772(m,2H),1.379(m,4H),1.358(m,4H),1.302(m,2H),1.267(m,2H),0.955(m,3H),0.595(m,3H)。
EXAMPLE 10 preparation of 3R- (indole-3-methyl) -6R- [4-Lys (Thr) -amino-n-butyl ] -2, 5-diketopiperazine (6b)
From 515mg (0.67mmol) of 3R- (indol-3-methyl) -6R- [4-Boc-Lys (Boc-Thr) -amino n-butyl using the method of example 2]-2, 5-diketopiperazine (5b) gave 247mg (64%) of the title compound as a colorless powder. ESI-MS (M/e):571[ M + H]+；1H NMR(300MHz,DMSO-d6):1H NMR(300MHz,DMSO-d6):δ/ppm＝10.947(s,1H),8.052(m,1H),7.994(m,2H),7.936(m,1H),7.578(d,J＝7.8Hz,1H),7.214(d,J＝7.8Hz,1H),7.026(m,2H),6.928(m,1H),4.117(m,2H),3.796(m,1H),3.506(m,1H),3.346(m,1H),3.253(dd,J1＝14.4Hz,J2＝3.6Hz,1H),3.039(m,3H),2.783(m,2H),1.592(m,1H),1.561(m,1H),1.467(m,2H),1.289(m,2H),1.060(d,J＝6.3Hz,1H),0.998(m,3H),0.595(m,3H)。
EXAMPLE 11 determination of the anti-tumor metastasis Activity of Compounds 6a, b
The assay model was inoculated with Lewis mouse lung carcinoma cells (LLC, purchased from ATCC) in DMEM medium (containing 10% inactivated fetal bovine serum, 1X 10)5U/L penicillin and 100mg/L streptomycin), and the cells are enriched by passage every two days according to an adherent cell culture method. Digesting the cells when the cells are in good growth state and in logarithmic growth phase, and adjusting the cell density to 1 × 10 with physiological saline7one/mL. Staining with placental blue to count viable cells>95 percent. Inbred C57BL/6 male mice (SPF grade, body weight 20. + -.2 g) were taken and left-handed mice fixed. The right anterior limb axillary skin of the mouse was disinfected with 75% ethanol. The LLC tumor cell suspension is injected subcutaneously into the axilla of a mouse with a 1mL sterile syringe held in the right hand, and 0.2mL is injected into each mouse. After the mice are inoculated for 10 days, tumors with the diameter of about 4-5mm grow out, namely the tumor source. The Lewis lung cancer tumor-bearing mice are inoculated for 10 days and anesthetized by ether, and then the cervical vertebrae are removed for killing. Soaking in 75% ethanol for 10min, sterilizing, and removing tumor on clean bench. Well-grown tumor tissue was selected, minced in a sterile plate, and placed in a tissue homogenizer made of glass. Adding physiological saline with the temperature of 4 ℃ according to the ratio of the tumor mass to the volume of the physiological saline of 1 to 3(g to mL), and lightly grinding to prepare the cell suspension. The cell suspension is screened by 200-mesh cells to prepare single cell suspension. Adjusting the cell density of the single cell suspension to 1.5X 10 with physiological saline7one/mL. Staining with placental blue to count viable cells>95 percent. Left-handed inbred C57BL/6 male mice were fixed and their right anterior limb axillary skin was disinfected with 75% ethanol. The tumor cell suspension was injected subcutaneously into the mouse axilla with a 1mL sterile syringe in the right hand, 0.2mL each. 10 days after inoculation, the mice developed tumors of 4-5mm in diameter, and the inoculated mice were randomly grouped by the measured tumor volume. Each group had 12 mice. On day 11 of tumor inoculation mice were either orally administered a recognized physiological saline solution of the anti-tumor metastasis peptide RGDS (at a dose of 20. mu. mol/kg/day) or orally administered a physiological saline solution of compounds 6a, b (at a dose of 0.5. mu. mol/kg/day) or orally administered a physiological saline solution (at a dose of 10 mL/kg/day), 1 dose per day, administered for 12 consecutive days, and tumor volumes were measured and recorded every other day. For the last administrationThe next day, tumor volume was measured, cervical spine was removed by ether anesthesia and sacrificed, mice tumors were weighed, mice lungs were taken and tumor nodules transferred from tumor lungs were counted. Statistical analysis of the data was performed using the t-test. The results are shown in Table 1. Not only was compound 6a, b effective in inhibiting tumor lung metastasis at the 0.5 μmol/kg dose, but the activity was not significantly different from RGDS at the 20 μmol/kg dose. These data indicate that the present invention has significant technical effects. Anti-tumor metastasis Activity of tables 16 a, b
a) P <0.01 to saline, p >0.05 to RGDS; n-10
Example 12 determination of dose dependence of anti-metastatic Activity of Compound 6a
The assay model was inoculated with Lewis mouse lung carcinoma cells (LLC, purchased from ATCC) in DMEM medium (containing 10% inactivated fetal bovine serum, 1X 10)5U/L penicillin and 100mg/L streptomycin), and the cells are enriched by passage every two days according to an adherent cell culture method. Digesting the cells when the cells are in good growth state and in logarithmic growth phase, and adjusting the cell density to 1 × 10 with physiological saline7one/mL. Staining with placental blue to count viable cells>95 percent. Inbred C57BL/6 male mice (SPF grade, body weight 20. + -.2 g) were taken and left-handed mice fixed. The right anterior limb axillary skin of the mouse was disinfected with 75% ethanol. The LLC tumor cell suspension is injected subcutaneously into the axilla of a mouse with a 1mL sterile syringe held in the right hand, and 0.2mL is injected into each mouse. After the mice are inoculated for 10 days, tumors with the diameter of about 4-5mm grow out, namely the tumor source. The Lewis lung cancer tumor-bearing mice are inoculated for 10 days and anesthetized by ether, and then the cervical vertebrae are removed for killing. Soaking in 75% ethanol for 10min, sterilizing, and removing tumor on clean bench. Well-grown tumor tissue was selected, minced in a sterile plate, and placed in a tissue homogenizer made of glass. The volume of the normal saline is 1 to 3(g to mL) according to the weight ratio of tumor mass) Adding physiological saline with the temperature of 4 ℃ into the mixture according to the proportion, and lightly grinding the mixture to prepare cell suspension. The cell suspension is screened by 200-mesh cells to prepare single cell suspension. Adjusting the cell density of the single cell suspension to 1.5X 10 with physiological saline7one/mL. Staining with placental blue to count viable cells>95 percent. Left-handed inbred C57BL/6 male mice were fixed and their right anterior limb axillary skin was disinfected with 75% ethanol. The tumor cell suspension was injected subcutaneously into the mouse axilla with a 1mL sterile syringe in the right hand, 0.2mL each. 10 days after inoculation, the mice developed tumors of 4-5mm in diameter, and the inoculated mice were randomly grouped by the measured tumor volume. Each group had 12 mice. Mice on day 11 of tumor inoculation were orally administered either a normal saline solution of the putative antitumor metastatic peptide RGDS (dose of 20. mu. mol/kg/day) or compound 6a (dose of 0.5. mu. mol/kg/day, 0.05. mu. mol/kg/day, 0.005. mu. mol/kg/day) or normal saline (dose of 10 mL/kg/day) 1 time daily for 12 consecutive days with tumor volumes measured and recorded every two days. The next day of the last administration, tumor volume was measured, cervical spine was removed by ether anesthesia and sacrificed, tumor of the mice was weighed, lung of the mice was taken and tumor nodules transferred from the lung of the tumor were counted. Statistical analysis of the data was performed using the t-test. The results are shown in Table 2. After the compound 6a can effectively inhibit the tumor lung metastasis at the dose of 0.5 mu mol/kg, the compound 6a can still effectively inhibit the tumor lung metastasis at the dose of 0.05 mu mol/kg, so that the effective dose is reduced by 400 times. These data indicate that the present invention has significant technical effects.
TABLE 2 determination of dose dependence of the anti-metastatic Activity of 6a
a) P <0.01 to saline, p >0.05 to RGDS, p >0.05 to 6a at a dose of 0.05. mu. mol/kg/day; b) p <0.05 to physiological saline, p <0.05 to 6a at a dose of 0.005 μmol/kg/day; c) p <0.05 to saline; n is 10.
EXAMPLE 13 determination of the anti-tumor growth Activity of Compounds 6a, b
Both doxorubicin and compound 6a, b were dissolved in physiological saline prior to assay for administration to S180 mice. Taking S180 ascites tumor liquid which is inoculated in a male ICR mouse and grows vigorously for 10 days in a sterile environment, diluting the S180 ascites tumor liquid into liquid (1:2) by using normal saline, fully mixing the liquid, dyeing the tumor cell suspension by using freshly prepared 0.2% trypan blue, uniformly mixing the liquid and the liquid, counting the liquid according to a white cell counting method, wherein the blue-dyed cell is a dead cell, and the non-dyed cell is a live cell. The cell concentration is 4-large-grid viable cell number/4 × 104The cell density was calculated as x dilution factor ═ cell number/mL, and the cell survival rate was calculated as live cell number/(live cell number + dead cell number) × 100%. Homogenizing tumor solution with survival rate of more than 90% to density of 2.0 × 107Cell suspension per mL. This cell suspension was inoculated subcutaneously (0.2 mL/mouse) in the right axilla of a mouse to prepare S180 tumor-bearing mice. 24h after inoculation, S180 tumor-bearing mice were intraperitoneally injected daily with a physiological saline solution of doxorubicin (dose 2. mu. mol/kg/day g) or orally administered daily with a physiological saline solution of compounds 6a, b (dose 0.5. mu. mol/kg/day). The administration is once daily for 12 days. The day after the last dose, tumor volume was measured, cervical spine was removed under ether anesthesia and sacrificed, then the right axillary tumor growth site of the mouse was fixed with forceps, and the skin was excised and the tumor was blunt-stripped and weighed. Efficacy was expressed as tumor weight (mean ± SD g), and data were analyzed by t-test and variance. The results are shown in Table 3. The data that compounds 6a, b were effective in inhibiting tumor growth at a dose of 0.5 μmol/kg indicate that the present invention has significant technical effects.
TABLE 3 Effect of Compounds 6a, b on tumor growth in S180 mice
a) P <0.01 to saline; n is 10.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810596333.3A CN110577518B (en) | 2018-06-11 | 2018-06-11 | Methyl indole and amide side chain amino acid modified diketopiperazine, synthesis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810596333.3A CN110577518B (en) | 2018-06-11 | 2018-06-11 | Methyl indole and amide side chain amino acid modified diketopiperazine, synthesis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110577518A CN110577518A (en) | 2019-12-17 |
| CN110577518B true CN110577518B (en) | 2021-06-08 |
Family
ID=68809518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810596333.3A Expired - Fee Related CN110577518B (en) | 2018-06-11 | 2018-06-11 | Methyl indole and amide side chain amino acid modified diketopiperazine, synthesis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110577518B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105272980A (en) * | 2014-06-10 | 2016-01-27 | 首都医科大学 | (3R,12aS)-3-(4-aminobutyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, and preparation and application thereof |
| CN105503833B (en) * | 2014-10-20 | 2019-07-02 | 首都医科大学 | Indolepiperazine-dione, its preparation and therapeutic effect |
| CN106349148B (en) * | 2015-07-13 | 2019-07-05 | 首都医科大学 | New indole class compound with anti-tumor metastasis and anti-inflammatory activity, synthesis and application |
-
2018
- 2018-06-11 CN CN201810596333.3A patent/CN110577518B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Enantiomeric diketopiperazines:getting insight into the impact of the configuration on the conformation,nanoimage,u-PA inhibition and anti-metastatic activity;Feng Wang et al.;《Med.Chem.Commun.》;20150331;第6卷(第9期);第956-962页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110577518A (en) | 2019-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110577518B (en) | Methyl indole and amide side chain amino acid modified diketopiperazine, synthesis and application thereof | |
| CN108948137B (en) | 3S-Indoleethyl-6S-polar amino acid-modified piperazine-2,5-diones, their synthesis, activities and applications | |
| CN110577568B (en) | Methyl indole and amide side chain amino acid modified diketopiperazine, synthesis, activity and application thereof | |
| CN110577517B (en) | Methyl indole and aromatic amino acid modified 2,5-diketopiperazine, their synthesis, activity and application | |
| CN108976201B (en) | 3R-indolylmethyl-6S-aromatic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN110551108B (en) | 3R-indolylmethyl-6R-amino acid modified 2, 5-diketopiperazines, synthesis, activity and use thereof | |
| CN108929320B (en) | 3R-indolylmethyl-6R-oxazolidinone modified piperazine-2, 5-dione, synthesis, activity and application thereof | |
| CN108929369B (en) | 3R-indolylmethyl-6R-acidic amino acid modified piperazine-2,5-dione, its synthesis, activity and application | |
| CN109134595B (en) | Curcumin modified by theanyl amino acid benzyl ester, its synthesis, activity and application | |
| CN108929313B (en) | 3R-indolylmethyl-6R-fatty amino acid modified piperazine-2,5-dione, its synthesis, activity and application | |
| CN109456311B (en) | 3R-indolylmethyl-6R-aromatic amino acid modified piperazine-2, 5-diketone and synthesis, activity and application thereof | |
| CN112898379A (en) | Dioxane-modified tetrahydrocarboline-3-formyl-The-HGE, preparation thereof, antitumor activity thereof and application thereof | |
| CN108948141B (en) | 3R-Indolylmethyl-6S-Pro-modified piperazine-2,5-diones, their synthesis, activities and applications | |
| CN108947975B (en) | 3S-indoleethyl-6S-fatty amino acid-modified piperazine-2,5-dione, its synthesis, activity and application | |
| CN108976204B (en) | 3S-indolylmethyl-6R-aspartic acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108976277B (en) | 3R-Indolylmethyl-6S-polar amino acid-modified piperazine-2,5-dione, its synthesis, activity and application | |
| CN108947977B (en) | Piperazine-2, 5-diketone modified by 3R-indolylmethyl-6R-amide side chain amino acid, and synthesis, activity and application thereof | |
| CN108947976B (en) | 3S-indolylmethyl-6S-aromatic amino acid-modified piperazine-2,5-diones, their synthesis, activities and applications | |
| CN108929315B (en) | 3R-indolylmethyl-6S-methionine modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN110551109B (en) | Amino acid and tranexamic acid modified diketopiperazine, preparation and application thereof | |
| CN108929314B (en) | 3R-indolylmethyl-6S-acidic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108976202B (en) | 3R-indolylmethyl-6S-Lys modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108947978B (en) | 3R-Indolylmethyl-6R-Tyr-modified piperazine-2,5-diones, their synthesis, activities and applications | |
| CN108976211B (en) | 3S-indolylmethyl-6R-aliphatic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN110551174B (en) | Amino acid and tranexamic acid modified diketopiperazines, their preparation, activity and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210608 |